{"id":"apo-methylphenidate-er","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Insomnia"},{"rate":"10-25","effect":"Decreased appetite"},{"rate":"5-15","effect":"Headache"},{"rate":"5-15","effect":"Nervousness or anxiety"},{"rate":"5-10","effect":"Tachycardia"},{"rate":"5-10","effect":"Elevated blood pressure"},{"rate":"5-10","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Methylphenidate inhibits the reuptake of dopamine and norepinephrine by blocking their respective transporters (DAT and NET), leading to increased concentrations of these neurotransmitters in the synaptic cleft. This enhanced dopaminergic and noradrenergic signaling improves attention, focus, and impulse control. The extended-release (ER) formulation provides sustained drug delivery over an extended period.","oneSentence":"Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the synapse.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:48.382Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD)"},{"name":"Narcolepsy"}]},"trialDetails":[{"nctId":"NCT05414058","phase":"PHASE2","title":"Adjunctive Methylphenidate ER in Patients With Schizophrenia to Improve Functional and Cognitive Outcomes","status":"COMPLETED","sponsor":"The Royal Ottawa Mental Health Centre","startDate":"2022-09-09","conditions":"Schizophrenia Schizoaffective","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":132262,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Apo-Methylphenidate ER","genericName":"Apo-Methylphenidate ER","companyName":"The Royal Ottawa Mental Health Centre","companyId":"the-royal-ottawa-mental-health-centre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the synapse. Used for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}